Skip to main content

Fixed-dose Combination of Hydralazine and Isosorbide Dinitrate Therapy for Self-identified Black or African American Patients with Heart Failure and LVEF <40% on ACEI or ARB and Beta-blocker Therapy

CBE ID
2764e
Project
Endorsed
Endorsement and Maintenance (E&M) Cycle
Is Under Review
No
Measure Description

Percentage of patients aged 18 years and older with a diagnosis of heart failure (HF) and a current or prior ejection fraction (EF) <40% who are self-identified Black or African Americans and receiving ACEI or ARB and Beta-blocker therapy who were prescribed a fixed-dose combination of hydralazine and isosorbide dinitrate seen for an office visit in the measurement period in the outpatient setting or at each hospital discharge

  • Measure Type
    Electronic Clinical Quality Measure (eCQM)
    Numerator

    Patients prescribed a fixed-dose combination of hydralazine and isosorbide dinitrate seen for an office visit in the measurement period in the outpatient setting or at each hospital discharge

    Denominator

    All patients aged 18 years and older with a diagnosis of heart failure with a current or prior EF <40% who are self-identified Black or African Americans and receiving ACEI or ARB and Beta-blocker therapy

    Exclusions

    Denominator exclusions include:
    o Hypotension (severe or symptomatic)
    o Severe lupus erythematosus
    o Unstable angina
    o Peripheral neuritis
    o Patient actively taking Phosphodiesterase Type 5 (PDE5) Inhibitors

  • Most Recent Endorsement Activity
    Approval for Trial Use Removed Cardiovascular Spring 2023
    Initial Endorsement
    Next Planned Maintenance Review
    Cardiovascular Spring 2023
    Endorsement Status
    Last Updated
    Removal Date
  • Steward Organization Email
    Steward Organization Copyright

    This documentation contains proprietary information, and is protected by U.S. copyright. All rights reserved.

    These Performance Measures (Measures) and all related data specifications have been developed by NMQF.

    No part of this documentation may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, modifying, or recording, without the prior written permission of National Minority Quality Forum (NMQF). No part of this documentation may be translated to another program language without the prior written consent of NMQF. Unauthorized posting of NMQF documents to a non-NMQF website is prohibited. The Measures, while copyrighted, can be reproduced and distributed, without modification, for noncommercial purposes, e.g., use by health care providers in connection with their practices. Commercial use is defined as the sale, license, or distribution of the Measure for commercial gain, or incorporation of the Measure into a product or service that is sold, licensed or distributed for commercial gain. Commercial uses of the Measure require a license agreement between the user and the NMQF. For information on reprint and linking permissions, please visit NMQF’s Terms of Use page (http://heartfailurequalityimprovementinitiative.com/terms-of-use/). Neither the NMQF, nor its members shall be responsible for any use of the Measures.

    © 2015 National Minority Quality Forum. All Rights Reserved.